1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Inapplicable: new trials by email Literature Review of Inapplicable trials Research Report on Inapplicable
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) DZD9008+AZD4205 - Non-small Cell Lung Cancer | Phase 2 | Completed | Dizal Pharmaceuticals | 30 | 2023-06-01 | 2026-10-22 |
| DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) DZD9008 plus Bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Dizal Pharmaceuticals | 60 | 2023-02-15 | 2025-06-19 |
Carcinoma, Non-Small-Cell Lung (2)
China (2)
Zhen Wang (1)